Suning Global, which has been suspended for half a year, released a restructuring plan on the evening of July 3. It is planned to purchase an 80% stake in Irmeigang Hua, a medical beauty hospital at a price of 208 million yuan. This is Suning Global's re-attack in the medical beauty industry since its cooperation with the Korean ID Health Group earlier this year.
According to the plan, Suning Global intends to acquire 80% of its total holding of Irmei Ganghua from Irmei Investment and Hong Kong and China Investment by way of issuing shares and paying cash, 40% of which is paid in cash, total payment 104 million yuan, the remaining 40% of the shares are intended to be issued by way of issuance of shares, the issue price is 10.8 yuan / share, the company needs to issue 97,196,000 shares to Irmei Investment. Upon completion of the transaction, Ilmer Hong Kong will become a holding subsidiary of Suning Global. Suning Global will add a medical beauty service business based on the real estate development business. This transaction does not constitute a major asset restructuring.
Established in June 2010, Yimeier Ganghua is a plastic surgery specialty hospital. Its main business is plastic surgery and beauty services, including plastic surgery services, cosmetic dermatology services, cosmetic dental services and beauty medicine services. The beauty service is mainly targeted at plastic and beauty consultation, medical services and private customized services for high-net-worth individuals. It also takes into account the basic plastic surgery services of the mid-end customer group and has strong brand influence in the Yangtze River Delta region.
It is understood that China's medical beauty institutions are roughly divided into two major components: public hospital plastic surgery and private medical beauty institutions. Most of the public hospital plastic surgery is only a routine part of the hospital, which is slightly insufficient in market development, customer mining and service experience. Private medical beauty hospitals have a market share of over 80%. China's medical beauty industry is expected to have a market size of more than 450 billion yuan in 2020, with an average annual compound growth rate of nearly 40%.
According to financial data disclosure, Yimeigang Port realized operating income of RMB 27.7351 million, RMB 19.712 million and RMB 38.110 million in 2014, 2015 and January-May 2016 respectively; net profit of RMB -89.919 million and RMB -143.336 million were realized respectively during the same period. And 8.496 million yuan.
The estimated 80% stake in Ilmer Hong Kong is 210 million yuan, with a value-added rate of 5902%. In terms of performance and valuation, Suning Global said that the operation of Immel Port China in the past few years focused on non-surgical projects, mainly injection projects, optoelectronic projects, its inherent characteristics lead to low profits, and from 2016 Since the beginning of the year, Irmei Hong Kong has carried out business strategy adjustments. On the one hand, it has vigorously strengthened the laying of marketing networks. On the one hand, the adjustment of business structure has been carried out. It is no longer limited to the original injection service projects, and the development center is transferred to surgical medical beauty. Service, this will also become an important profit growth point for the company in the future.
Nutrition Maltodextrin Powder,Maltodextrin Supplements,Maltodextrin Gluten Free
Shandong Bailong Chuangyuan Bio-tech Co.,Ltd. Qingdao Branch , https://www.sdblcycn.com